Vertex Ventures HC’s Post

Prominent Ophthalmology Deal in H1’24 As July culminates, so does our exploration of Ophthalmology! Octavus Consulting navigated nuanced aspects of Eye diseases/ophthalmic conditions throughout July. To wind up our theme, we bring a condensed overview of the deal in Ophthalmology that remained in the news in H1’24. Reach out to us at [email protected] for: 1. Investor Call Reports 2. Deep Dive Deals Analyses 3. Curated Financial Reports 4. Products/Assets Analyses 5. Secondary Due Diligence Merck EyeBio #ophthalmologynews #acquisition #milestone #investorcall #dealanalysis #financereports #healthcare #biotech #pharma #biopharma #octavusconsulting

Combination therapies , reduce treatment burden & more personalized approach : That’s the way I like it for a very long time… « Around 15 years ago, vascular endothelial growth factor-A (VEGF-A) inhibitors revolutionized eye care by offering an effective way to treat certain retinal diseases, but we now understand more about the potential limits of this approach. For instance, not everyone achieves a good outcome with anti-VEGFs. It is plausible that these complex diseases cannot be treated by targeting only one cytokine. Additionally, we’re pushing up against something of an “efficacy ceiling” with anti-VEGF treatments. And that is something the team I work with are really laser-focused on: how can we break this status quo? It’s a significant challenge and one Roche is tackling from multiple angles. As a community, I do believe we are making great strides, and I’m optimistic that the next big breakthrough is on the horizon. Secondly, and perhaps with a more long-term perspective, I think it’s going to be critical to move beyond control of disease and towards more preventative and even regenerative treatment approaches. We all know our population is aging, and with that we expect to see significant increases in retinal diseases. We’re not there yet, but the science and the technology are definitely maturing and so my hope – my belief – is that we will be able to shift from treating vision loss towards reversing, and even curing it, in the not-too-distant future. How can combination therapies improve on the standard of care? Combination therapies are exciting as they have the potential to address the mechanisms that are driving retinal disease from multiple angles at once with several potential benefits. First and foremost, there is the potential for improvements in vision outcomes for patients. It may be the key to surpassing the efficacy ceiling we are currently seeing with anti-VEGF treatments. Additionally, combination therapies have the potential to reduce treatment burden by using lower doses of complementary therapies rather than relying on escalating doses of monotherapy. In the future, combination treatments could also provide a more personalized approach to care in retinal disease. If we can successfully develop a number of combination therapies targeted to different pathways, it would offer flexibility to tailor the treatment approach to individual patients. »

Sometimes M&A activity creates barriers for the competition and other times it opens up opportunities… if the landscape you work in is changing and you are unsure how to convert a perceived barrier to an opportunity, reach out to our expert Market Analysis and Strategic Planning experts. #strategicplanning #orthopaedics #regenmed

Watch the on-demand Ophthalmology Panel Discussion and gain expert insights through engaging conversations with leading experts about the future of ophthalmology clinical trials and how to identify solutions in an uncertain market. https://hubs.la/Q026yPZ40 #Ophthalmology #pharma #biotech #clinicaltrials #biostatistics #CROpartner

Izervay (avacincaptad pegol intravitreal solution; Astellas Pharma) demonstrated positive results in the GATHER2 Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), according to data presented at AAO 2023. Read the full article here ⤵️ #AAO2023 #maculardegeneration #geographicatrophy

Watch the on-demand Ophthalmology Panel Discussion and gain expert insights through engaging conversations with leading experts about the future of ophthalmology clinical trials and how to identify solutions in an uncertain market. https://hubs.la/Q026yLNZ0 #Ophthalmology #pharma #biotech #clinicaltrials #biostatistics #CROpartner

In July, Octavus Consulting is navigating Ophthalmology as a theme! Dry Age-Related Macular Degeneration (AMD) affects the retina, and the person loses central vision. However, the condition does not affect the peripheral vision. It is one of the leading causes of vision loss in people 50 years and above. Today, let's look into the competitive landscape of Dry Age-Related Macular Degeneration (AMD). Draw insights from our meticulously prepared competitive landscape with a glimpse of assets from several biopharma companies working in Dry AMD. Our competitive landscape service provides comprehensive competitor mapping to keep you ahead of the curve all the time. With our thorough portfolio assessment, we keep you up-to-date on competitors' pipeline candidates and marketed products. Moreover, our competitive landscape offering includes a trend assessment to help understand the ever-evolving healthcare market. Open the doors to endless opportunities and growth by reaching out to us at [email protected] #competitivelandscape #competitors #dryagerelatedmaculardegeneration #dryamd #competitorinsights #pcd #pipelinecandidates #biopharma #biotech #ophthalmology #octavusconsulting

🔍 Exploring Dry AMD Landscape: Key Insights In July, Octavus Consulting delved into the fascinating world of ophthalmology, focusing on dry age-related macular degeneration (AMD). Our team meticulously crafted a landscape and profiling for this rare indication. Here are the key takeaways: ➡ Approved Molecules: ♦ A total of 3 molecules has received approval, with 2 specifically targeting Geographic Atrophy (GA). ♦Astellas Pharma secured FDA approval for Izervay in Aug 2023, raking in an impressive revenue of 💴66B (~$43M). Astellas Pharma is also evaluating ASP7317, a promising cell therapy in P-I trials. ♦Apellis Pharmaceuticals’ Syfovre gained FDA approval in Feb 2023, contributing to a revenue of around $275M. ➡Pathways and Players: ♦The landscape features 6 molecules, divided between the complement (2) and alternate pathways (4). ♦Notably, both Syfovre (Apellis Pharmaceuticals) and Izervay (Astellas Pharma) act as complement pathway inhibitors. ♦Other contenders include AstraZeneca’s Danicopan (P-II), Ionis Pharmaceuticals, Inc. & Roche’s RG6299 (P-II), Novartis’ Iptacopan (P-II), and GT005 (P-II). ➡Upcoming Approvals: 🎯Keep an 👀eye out for P-III ALK-001 by Alkeus Pharmaceuticals, Inc., expected to receive approval in Jan 2025. 🎯Stealth BioTherapeutics is also on the horizon with Elamipretide by 2027. 📥 Get the Landscape PDF: Comment below, and we’ll send you a high-quality landscape directly via DM. If you’re seeking a deeper dive into the dry AMD or ophthalmology space, feel free to reach out at [email protected] to schedule a call. 🚀 Let’s make this knowledge go viral! Share your thoughts and insights. 🌟 #DryAMD #Ophthalmology #HealthcareInsights #PharmaTrends #pharmainsights #competitiveanalysis #intelligence #competitiveintelligence

Happy Friday - here is our weekly dive into news and updates across #woundcare, #diabetes, #footandankle and #limbsalvage. 📅 ******************************************* 📈 Financial 📈 Aroa Biosurgery Limited announced full-year sales of NZ$69.1M up 12%. Myriad up 73%, Endoform down 2% and TELA Bio down 7%. US sales reported growth to 242 accounts and 17.5% increase in sales by rep. Solventum is targeted by activist investor Trian Fund Management, L.P. now one of the largest shareholders. They feel the company should re-accelerate organic growth, restore margins and simplifying its portfolio. Upcoming Earnings: Integra LifeSciences – 7/29/24 Stryker – 7/30/24 MiMedx – 7/31 CONMED Corporation – 7/31/24 Tandem Diabetes Care Diabetes – 8/1/24 Organogenesis – 8/8/24 Orthofix – 8/6/24 Enovis – 8/7/24 Paragon 28 – 8/8/24 Treace Medical Concepts, Inc. – 8/6/24              Zimmer Biomet – 8/7/24 Solventum – 8/8/24 AVITA Medical – 8/8/24 Sanara MedTech – 8/12/24 ******************************************* 📢 News 📢 Jeffrey Shuren is departing the FDA after 15 years of leading the CDRH. He created the breakthrough devices program and during his tenure, the number of medical devices authorized by the FDA increased five-fold. Biogennix is entering woundcare through the launch of Agilon Surgical Matrix, 100% bovine Type 1 collagen with antimicrobial properties. Spectral AI announced a 30% increase in its patent portfolio for its AI-driven wound assessment platform. Total patents now at 26 granted and 38 pending in support of #AI driven DeepView System. Forma Medical Inc announced the launch of their newest product, OptimalMTP providing a dedicated MIS MTP fusion solution, furthering their position as the only company focused on MIS solutions for the forefoot. HealthpointCapital announced their inaugural investor day to coincide with the 14th Annual Orthopaedic Summit: (OSET) meeting in September. Notable participants include executives from Anika, ATI- Advanced Medical Technologies Ltd, DePuy Synthes, Johnson & Johnson MedTech, Stryker, THINK Surgical, United Orthopedic Corporation, Smith+Nephew, and Zimmer Biomet. ******************************************* FDA commissioner Robert Califf delivered the keynote address to the American Diabetes Association announcing - We are failing patients with diabetes. He pointed that diabetes passed cancer as the leading economic cost to our health care system, adding up to over $400bn annually. leading causes - Poor diets, poor labeling, economic disadvantages and health inequity. #DigitalHealth called out as needing to help drive solutions, which thus far we have not seen. ******************************************* That’s it for this week, until next time. #woundcare #chronicwounds #limbsalvage #footandankle #diabetesmanagement #chronicdisease